JP7150409B2 - An agent for completely curing allergic rhinitis (hay fever) by isolating IgE antibodies attached to mast cells in the nasal mucosa. - Google Patents
An agent for completely curing allergic rhinitis (hay fever) by isolating IgE antibodies attached to mast cells in the nasal mucosa. Download PDFInfo
- Publication number
- JP7150409B2 JP7150409B2 JP2015225153A JP2015225153A JP7150409B2 JP 7150409 B2 JP7150409 B2 JP 7150409B2 JP 2015225153 A JP2015225153 A JP 2015225153A JP 2015225153 A JP2015225153 A JP 2015225153A JP 7150409 B2 JP7150409 B2 JP 7150409B2
- Authority
- JP
- Japan
- Prior art keywords
- nasal
- hay fever
- allergic rhinitis
- mast cells
- nasal mucosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
Description
本願発明は鼻粘膜．の肥満細胞に附着しているＩｇＥ抗体を分離させることによって、アレルギー性鼻炎（花粉症）を完治させるための剤に関するものである。The present invention relates to nasal mucosa. The present invention relates to an agent for completely curing allergic rhinitis (hay fever) by isolating IgE antibodies attached to mast cells.
現代医学による花粉症の治療方法・治療薬には次の様な欠点がある。
（１）一度、花粉症に罹ると一般的に完治することがない。というのが現代医学の常識である。そのために抗原（花粉）の飛散する時には、常にそれがなくなるまで薬を服用し続けなければ不快な症状（くしゃみ・鼻閉・鼻汁の流出）を回避することが出来ない。
花粉症の治療としては、以下の治療方法と治療薬がある。
（Ａ）治療方法としては、以下のものがある。
（１）凝固壊死法（高周波凝固法、レーザー法。トリクロール酢酸法など）
（２）切除法（下鼻甲介粘膜広範囲切除法）
（３）ビディアン神経切断術法
（４）減感作療法
（５）理学療法（スチーム吸入療法）
（６）新しい治療法▲Ａ▼抗ＩｇＥ抗体療法▲Ｂ▼アナフィラキシー誘発を抑制した免疫療法▲Ｃ▼舌下抗原特異的免疫療法
（７）Ｎａｔｕｒｅ４１３：４２０－４２５．２００１［アレルギー・ぜんそく研究所］Ｊｕｔｅｌ．ｅｔａｌ（スイス国籍）「ヒスタミンが、ヒスタミンＨ１・Ｈ２受容体の発現によりＴ細胞と抗体反応を調節する。」の論文によれば「ヒスタミン自身が、アレルギーを終息させる物質として働いている。即ち、ヒスタミンは、Ｈ１受容体を介してＩＦＮｒ、即ち、Ｔｈ１系のサイトカインを産生・増強する。生体においては。ヒスタミン量が多くなるとＩＦＮｒが増え、Ｔｈ２の細胞の分化を抑えて、ＩＬ－４や、ＩＬ－１３の産生を抑制し、ＩｇＥ産生を抑え、アレルギーを終息させる。」（最新医学別冊アレルギー性鼻炎免疫２ ２００３年刊）とある。［非特許文献１］
この理論は、本願発明の生理作用（反応）の理論的根拠のひとつである。
（８）鼻粘膜上皮細胞はアレルギー発症ごおいて重要な場＝であると当時に、Ｔｈ２優位な環境成立に至る過程で重要な役割を担っている。これまで好酸球や肥満細胞、Ｔ細胞といった反応担当細胞にアレルギー研究の重点が置かれていたが、鼻粘膜におけるアレルギー発症のメカニズムを考えた場合、上皮細胞が極めて重要な役割を担っていることが明らかになってきた。今後上皮をターゲットした新たな治療に結びつくような研究の展開が期待される。［非特許文献２］
（９）免疫寛容は、以下の時に発生する。
▲１▼生まれたときに抗原が入る。▲２▼抗原がものすごく微量か、逆に大量の時。
▲３▼抗原を口から入れた時。（経口寛容）
▲イ▼反応性を持っている細胞の消去。（反応の欠損）
▲ロ▼細飽を無力化する。（アナジー現象）
▲ハ▼反応しようとすると、ほかの細胞が反応を抑えてしまう。
［非特許文献３］免疫学個人授業多田富雄・南伸坊著講談社刊第１１講和
（１０）Ｂ細胞、肥満細胞をＰＨ３の強酸で処理すれば、Ｂ細胞、肥満細胞表面のＦｃレセプターから、血清由来のＩｇＥ抗体が分離する。［非特許文献４］
（Ｂ）治療薬としては以下のものがある。
（１１）抗鼻炎・アレルギー剤として梅干のエキスを主とするものがある。
特許文献１には、梅干の製造過程で生じる生産物およびしそづけ梅干を主原料とするカプセル状の抗鼻炎・抗アレルギー剤が記載され、カプセルを鼻へ挿入して鼻栓をしたのち、鼻栓を開放して発生した鼻汁をかむことを３回繰り返す使用方法が記載されている（請求項、実施例）．そして、当該抗鼻炎・抗アレルギー剤は梅、しそ、塩あるいはそれらから製造される梅干の成分による作用で強力な抗炎症作用、アレルゲンの消滅、抗アレルゲン体質化が得られる旨が記載されている（［０００１０］）．なお、梅干にはクエン酸・リンゴ酸等の有機酸が含まれている．（非特許文献６）
上記（１）～（７）は非特許文献１に記載してある。
上記（８）は、非特許文献２に記載してある。
上記（９）は非特許文献３に記載してある。
上記（１０）は、非特許文献４に記載してある。
上記（ｌｉ）は、特許文献１ 特許文献２、非特許文献５、非特許文献６に記載してある。Modern medical treatment methods and drugs for hay fever have the following drawbacks.
(1) Once you get hay fever, it is generally not completely cured. This is the common sense of modern medicine. Therefore, when antigens (pollen) scatter, unpleasant symptoms (sneezing, nasal congestion, discharge of nasal discharge) cannot be avoided unless the medicine is continued to be taken until the antigens (pollen) disappear.
Pollinosis is treated with the following therapeutic methods and therapeutic agents.
(A) Treatment methods include the following.
(1) Coagulation necrosis method (high frequency coagulation method, laser method, trichloracetic acid method, etc.)
(2) Resection method (inferior turbinate mucosa wide resection method)
(3) Vidian nerve cutting method (4) Hyposensitization therapy (5) Physical therapy (steam inhalation therapy)
(6) New therapeutic method (A) Anti-IgE antibody therapy (B) Immunotherapy suppressing anaphylaxis induction (C) Sublingual antigen-specific immunotherapy (7) Nature 413: 420-425.2001 [Research Institute for Allergy and Asthma] Jutel. et al (Switzerland) "Histamine modulates T - cell and antibody responses through the expression of histamine H1 and H2 receptors." That is, histamine produces and enhances IFNr, that is, Th 1 system cytokine through H 1 receptors.In the body, when the amount of histamine increases, IFNr increases, suppressing the differentiation of Th 2 cells, It suppresses the production of IL-4 and IL-13, suppresses the production of IgE, and terminates allergies.” [Non-Patent Document 1]
This theory is one of the theoretical bases of the physiological action (reaction) of the present invention.
(8) At that time, nasal mucosal epithelial cells play an important role in the process leading to the establishment of a Th2-dominant environment, as they are an important site in the onset of allergy. Until now, allergy research has focused on response cells such as eosinophils, mast cells, and T cells, but when considering the mechanism of allergy development in the nasal mucosa, epithelial cells play an extremely important role. It has become clear. In the future, it is expected that research will lead to new treatments targeting the epithelium. [Non-Patent Document 2]
(9) Immune tolerance occurs when:
(1) Antigens enter at birth. (2) When the amount of antigen is extremely small or, conversely, is large.
(3) When an antigen is put in the mouth. (oral tolerance)
▲ B ▼ Erasure of cells having reactivity. (Response deficit)
▲ B ▼ Incapacitate Saku. (Anergy phenomenon)
▲C▼ When you try to react, other cells suppress the reaction.
[Non-Patent Document 3] Immunology Individual Class Written by Tomio Tada and Shinbo Minami Vol. Serum-derived IgE antibodies are separated. [Non-Patent Document 4]
(B) Therapeutic agents include the following.
(11) There are anti-nasal and allergy agents that are mainly composed of umeboshi extract.
Patent Document 1 describes a capsule anti-rhinitis/anti-allergic agent mainly composed of a product produced in the manufacturing process of umeboshi and a pickled umeboshi. The method of use is described in which the stopper is opened and the generated nasal discharge is chewed three times (claims, examples). It is also stated that the anti-nasal inflammation/anti-allergic agent has a strong anti-inflammatory effect, elimination of allergens, and anti-allergen constitution by the action of ume, perilla, salt, or the components of umeboshi produced from them. ([00010]). Umeboshi contains organic acids such as citric acid and malic acid. (Non-Patent Document 6)
The above (1) to (7) are described in Non-Patent Document 1.
The above (8) is described in Non-Patent Document 2.
The above (9) is described in Non-Patent Document 3.
The above (10) is described in Non-Patent Document 4.
The above (li) is described in Patent Document 1, Patent Document 2, Non-Patent Document 5, and Non-Patent Document 6.
現代医学による花粉症の治療方法・治療薬には次の様な欠点がある。
（１）一度、花粉症に罹ると一般的に完治することがない、というのが現代医学の常識である。そのために抗原（花粉）の飛散する時には、常にそれがなくなるまで薬を服用し続けなければ不快な症状（くしゃみ・鼻閉・鼻汁の流出）を回遊することが出来ない。
（２）免疫療法もあるが長期の通院を要し、またすべての患者に有効なものでもない。そもそも、免疫療法という発想自体が花粉症の生理作用機序に反する。細菌やウイルスは細胞内に侵入して活動するために体の生理作用で。それを体外に徘出して、その活動を防ぐことが出来ない。しかし、花粉症は、細胞外での症状である。花粉症の治療に免疫療法を利用すること、使用することは、体の生理作用に基本的に反することである。したがって、根本的な問題解決策になりえない。
（３）手術療法などもあるが、花粉症は、生体にダメージを与えずに治療出来る。
（４）その他新しい治療方法・治療薬も開発されているが、いずれも花粉症の症状を病的生理作用と、とらえて対応するから完治方法・完治薬がみつからない。既存の治療方法は、費用・時間・効果・副作用の心配等々の問題があり、また、花粉症を完治させることは、困難である。
（５）既成の花粉症の治療剤（鼻粘膜層からの鼻汁の持続的発生・流出とその浮腫による鼻閉による不快感・くしゃみの解消を目的とする薬剤）には、その症状の発生を抑えることを目的に開発された薬剤が使用される。しかし、その薬剤によって花粉症の症状は、一時、抑制されるが、花粉症を完治させる薬剤ではない。そのために花粉の飛散している限り、症状が発生するために薬を服用し続けなければならない。花粉症の生理作用機序は解明されているから、その生理作用機序を活用・利用して、花粉症を完治さす方法・薬剤の開発は、現代医学の緊急の課題である。
（６）アレルギー性鼻炎（花粉症）の発症は、鼻粘膜上皮層への感作肥満細胞の集積から始まる。アレルギー性鼻炎（花粉症）を速効的に完治させるために、鼻粘膜の肥満細胞に付着しているＩｇＥ抗体を分離させて、アレルギー性鼻炎（花粉症）を完治させるための治療に使用する剤の発明が、本願発明の課題である。Modern medical treatment methods and drugs for hay fever have the following drawbacks.
(1) It is common knowledge in modern medicine that once a person suffers from hay fever, it is generally not completely cured. Therefore, when the antigen (pollen) scatters, the unpleasant symptoms (sneezing, nasal congestion, discharge of nasal discharge) cannot be relieved unless the medicine is continuously taken until the antigen (pollen) disappears.
(2) There is also immunotherapy, but it requires long-term hospital visits and is not effective for all patients. In the first place, the idea of immunotherapy itself runs counter to the physiological action mechanism of hay fever. Bacteria and viruses are physiological actions of the body to invade and work in cells. It cannot escape from the body and prevent its activity. However, hay fever is an extracellular symptom. The utilization and use of immunotherapy to treat hay fever is fundamentally contrary to the body's physiology. Therefore, it cannot be a fundamental solution to the problem.
(3) There are surgical treatments, but hay fever can be treated without damaging the body.
(4) Other new therapeutic methods and therapeutic drugs have been developed, but all treat the symptoms of hay fever as pathophysiological effects, so no cure methods or drugs have been found. Existing treatment methods have problems such as cost, time, effect, and side effects, and it is difficult to cure hay fever completely.
(5) Existing therapeutic agents for hay fever (drugs aimed at resolving discomfort and sneezing caused by nasal congestion due to continuous generation and outflow of nasal mucus from the nasal mucosa layer and its edema) do not cause the symptoms. Medications designed to control it are used. However, although the drug temporarily suppresses the symptoms of hay fever, it is not a drug that completely cures hay fever. For that reason, as long as pollen is scattered, you must continue to take the medicine in order to develop symptoms. Since the physiological action mechanism of pollinosis has been elucidated, it is an urgent task of modern medicine to develop methods and drugs that can completely cure pollinosis by utilizing the physiological action mechanism.
(6) The onset of allergic rhinitis (hay fever) begins with accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa. An agent used for the complete cure of allergic rhinitis (hay fever) by isolating the IgE antibody attached to the mast cells of the nasal mucosa in order to cure the allergic rhinitis (hay fever) quickly. is the subject of the present invention.
（１）鼻粘膜の肥満細胞の附着しているＩｇＥ抗体を分離させて、アレルギー性鼻炎（花粉症）を完治させるための治療に使用する本願発明の剤は、以下の構成である。重量２０％の食用塩、重量９０％のクエン酸を主成分とする重量５％でＰＨ３の有機酸からなる。（２）鼻粘膜の肥満細胞に付着しているＩｇＥ抗体の分離のために、本剤を、鼻腔の大きさに適した日本薬局方カプセル（例えば＃００、＃０、＃等）に入れて、鼻腔内に挿入し、鼻閉すると鼻粘膜層における塩と有機酸の酸による生理反応、即ち、食用塩とＰＨ３の有機酸の酸による脱水・萎縮反応と、食用塩とＰＨ３の有機酸の酸による刺激とストレスを鼻粘膜層に与える。
（３）本剤による治療の過程で、鼻粘膜内の肥満細胞のＦｃレセプターから、アレルギー発症の原因になるＩｇＥ抗体を分離さすためにＰＨ３の有機酸で鼻粘裏をひたす。その結果、鼻粘膜の肥満細胞から、ＩｇＥ抗体が分離し、鼻粘膜上皮層の感作肥満、細胞の集積を解消する。
［非特許文献４］未来免疫学 安保徹著 インターメディカル社刊第二章気圧と酸素と白血球（Ｐ－４５～４６）１９９７年刊
（４）上記（２）（３）の課題は、アレルギー性鼻炎（花粉症）が発症した時に本願発明の剤を鼻腔内に挿入し、鼻閉する。
しばらくすると、本剤が溶けてその成分が鼻粘膜層と生理反応をおこし始める。すると、鼻汁が発生し始め、鼻腔内に鼻汁が溜まり始める。この反応をできるだけ長く辛抱し、辛抱し、きれなくなったら、鼻をかみ続ける。数回から１０回程、とにかく、鼻汁が出なくなるまで、鼻をかみ続ける。そして、鼻汁が出なくなれば、再度、本剤を鼻腔内に挿入すると、それが、溶けて、その成分が、鼻粘膜層と再度反応をおこし始める。すると、上記の様に、鼻腔内に鼻汁が溜り始める。この反応を出来るだけ長く辛抱し、辛抱しきれなくなれば、鼻汁が出なくなるまで鼻をかむ。そして、その後、初回と同じ様に、再々度、本剤を鼻腔内に挿入し、鼻汁のたまるのを待ち、鼻汁が増えなくなったことが、確認出来れば、鼻汁が出なくなるまで、鼻をかみ続ける。鼻汁は、初回より、２回目、２回目より３回目の方が、発生量は少なくなる。この３回の治療によって、アレルギー性鼻炎（花粉症）の症状である鼻汁の流出と鼻閉の症状等は、一時、解消する。しかし、後日、又、アレルギー性鼻炎（花粉症）が発症する。その症状が、これ以上悪くならないと思った時に、２度目の治療をする。初回と同じ治療方法と治療回数を実施すれば、アレルギー性鼻炎（花粉症）の症状が解消する。そして、完全を期するために、後々日、発生するアレルギー性鼻炎（花粉症）の症状を見逃さず３度目の治療を上記の様に実施する．因に鼻粘膜層のＰＨは、７－８である。(1) The agent of the present invention, which is used for treating allergic rhinitis (hay fever) by isolating the IgE antibody attached to mast cells in the nasal mucosa, has the following composition. It consists of 20% by weight edible salt, 5% by weight PH 3 organic acid based on 90% by weight citric acid. (2) For the separation of IgE antibodies attached to mast cells of the nasal mucosa, put this agent in Japanese Pharmacopoeia capsules (e.g., #00, #0, #, etc.) suitable for the size of the nasal cavity. , is inserted into the nasal cavity, and when the nose is blocked, the physiological reaction of salt and organic acid in the nasal mucosa layer, that is, the dehydration and atrophy reaction of edible salt and organic acid of PH3 due to acid, and the reaction of edible salt and organic acid of PH3. Gives acid stimulation and stress to the nasal mucosa layer.
(3) In the course of treatment with this drug, the lining of the nasal mucous membrane is soaked with a PH3 organic acid in order to separate the IgE antibody that causes allergy from the Fc receptors of mast cells in the nasal mucosa. As a result, the IgE antibody is separated from mast cells of the nasal mucosa, and the sensitized obesity and accumulation of cells in the epithelial layer of the nasal mucosa are eliminated.
[Non-Patent Document 4] Mirai Immunology, Toru Abo, Intermedical Co., Ltd., Chapter 2 Atmospheric Pressure, Oxygen and Leukocytes (P-45-46), 1997 (4) Problems of (2) and (3) above are allergic rhinitis When (hay fever) develops, the agent of the present invention is inserted into the nasal cavity to cause nasal congestion.
After a while, the drug dissolves and its ingredients begin to cause a physiological reaction with the nasal mucosa layer. Then, nasal discharge begins to occur, and nasal discharge begins to accumulate in the nasal cavity. Be patient with this reaction for as long as you can, be patient, and when you get stuck, keep blowing your nose. Continue blowing your nose several to ten times until no more mucus is produced. Then, when nasal discharge ceases, inserting this drug into the nasal cavity again causes it to dissolve, and its ingredients begin to react with the nasal mucosa layer again. Then, as described above, nasal mucus begins to accumulate in the nasal cavity. Patience with this reaction as long as you can, and if you can't stand it, blow your nose until no more mucus is produced. After that, insert this drug into the nasal cavity again in the same way as the first time, wait for the nasal discharge to accumulate, and if you can confirm that the nasal discharge has stopped increasing, blow your nose until the nasal discharge stops. continue. The amount of nasal discharge produced is smaller at the second time than at the first time, and at the third time than at the second time. With these three treatments, the symptoms of allergic rhinitis (hay fever) , such as runoff of nasal discharge and nasal congestion, are temporarily relieved. However, at a later date, allergic rhinitis (hay fever) also develops. When you think the symptoms won't get any worse, do the second treatment. The symptoms of allergic rhinitis (hay fever) will disappear if the same treatment method and number of treatments as the first treatment are performed. Then, in order to ensure completeness, the third treatment is carried out as described above without overlooking the symptoms of allergic rhinitis (hay fever) that will occur later in the day. Incidentally, the pH of the nasal mucosa layer is 7-8.
前記の課題を解決するための手段、および、後記の発明を実施するための形態に記載の様に、鼻粘膜の肥満細胞のＦｃレセプターから、アレルギー発症の原因になるＩｇＥ抗体を分離さすために重量２０％の食用塩、重量９０％のクエン酸を主成分とする重量５％でＰＨ３の有機酸の剤を鼻腔の大きさに適した日本薬局方カプセル（例えば、＃００、＃０、＃等）に入れて鼻腔内に入れ、３度９回の治療によって、下記の（１）（２）（３）（４）の生理反応が発生し、アレルギー性鼻炎（花粉症）の症状が解消し．そして再発せず、アレルギー性鼻炎（花粉症）は完治する。（１）上記本剤で治療する過程で．即ち。肥満細胞をＰＨ３の強酸で処理した（非特許 文献４）のと同じ生理反応が発生して、それらの細胞膜表面のＦＣレセプターから血清由来のＩｇＥ抗体が分離し、鼻粘膜上皮層の花粉症の発症のトリガーになる感作肥満細胞の集積が解消する。その結果、抗原抗体反応が発生しなくなり、アレルギー性鼻炎（花粉症）は完治する。下記にその説明をする。
（２）アレルギー性鼻炎（花粉症）の発症の原因は、鼻粘膜上皮層への感作肥満細胞の集積から始まる。この３度９回の治療によって鼻粘膜層に存在する抗原抗体反応に関係するものが、その機能を喪失解消する。
（３）食用塩とＰＨ３の有機酸からなる本剤の治療の課程で鼻粘膜の肥満細胞からＩｇＥ抗体が分離することにより、アレルギー性鼻炎（花粉症）の発症のトリガーになる感作肥満細胞の鼻粘膜上皮層への集積が解消する。その結果、抗原抗体反応が発生しなくなり、アレルギー性鼻炎（花粉症）は完治する。
（４）上記本剤の治療の課程で、ＰＨ３の有機酸に鼻粘膜をひたすことにより、鼻粘膜の肥満細胞からＩｇＥ抗体が分離し、鼻粘膜上皮層の感作肥満細飽の集積が解消して、抗原抗体反応が発生しなくなり、アレルギー性鼻炎（花粉症）は完治する。
（５）既存のアレルギー性鼻炎（花粉症）の治療剤には、上記の生理反応を利用、いかすという発想がない。この生理反応を利用、いかすために、本願発明の剤の鼻腔内への挿入を繰返すことによって、鼻粘膜上皮層の感作肥満細胞の集積が解消する。
本剤による治療の課程で、鼻粘膜の肥満細胞から、ＩｇＥ抗体が分離して、鼻粘膜上皮層の感作肥満細胞の集積が解消して、抗原抗体反応が発生しなくなり、アレルギー性鼻炎（花粉症）は完治する．
（６）上記本剤の治療の過程で、ＰＨ３の有機酸の本剤で鼻粘膜を浸すことになり、鼻粘膜の肥満細胞から、アレルギーを起すＩｇＥ抗体が分離して、鼻粘膜上皮層の肥満細胞から抗体が分離し、花粉症発症のトリガーになる鼻粘膜上皮層の感作肥満細胞の集積が解消して、抗原抗体反応か発生しなくなり、アレルギー性鼻炎（花粉症）は完治する。Means for solving the above problems and, as described in the mode for carrying out the invention described later, for separating IgE antibodies that cause allergy development from Fc receptors of mast cells in the nasal mucosa 20% by weight of edible salt, 90% by weight of citric acid as the main component, 5% by weight of an organic acid agent with a pH of 3. Japanese Pharmacopoeia capsules suitable for the size of the nasal cavity (e.g., #00, #0, # etc.) and put it in the nasal cavity, and after 3 to 9 treatments, the following physiological reactions (1), (2), (3), and (4) occur, and the symptoms of allergic rhinitis (hay fever) are resolved. death. And there is no recurrence, and the allergic rhinitis (hay fever) is completely cured. (1) During the course of treatment with this drug. Namely. When mast cells were treated with a strong acid of PH3 (Non-Patent Document 4), the same physiological reaction occurred, and serum-derived IgE antibodies were separated from the FC receptors on the surface of their cell membranes, causing hay fever in the epithelial layer of the nasal mucosa. Accumulation of sensitized mast cells, which triggers the onset, disappears. As a result, antigen-antibody reactions cease to occur, and allergic rhinitis (hay fever) is completely cured. I will explain it below.
(2) The cause of the onset of allergic rhinitis (hay fever) begins with the accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa. With these 3 times and 9 treatments, the functions related to the antigen-antibody reaction existing in the nasal mucosa layer are lost and resolved.
(3) Sensitized mast cells that trigger the onset of allergic rhinitis (hay fever) by isolating IgE antibodies from mast cells in the nasal mucosa during the course of treatment with this drug, which consists of edible salt and a pH3 organic acid. accumulation in the epithelial layer of the nasal mucosa is resolved. As a result, antigen-antibody reactions cease to occur , and allergic rhinitis (hay fever) is completely cured.
(4) In the course of treatment with this drug, IgE antibodies are separated from mast cells in the nasal mucosa by soaking the nasal mucosa in an organic acid of pH3, and the accumulation of sensitized obesity in the epithelial layer of the nasal mucosa is resolved. As a result, antigen-antibody reactions cease to occur, and allergic rhinitis (hay fever) is completely cured.
(5) Existing therapeutic agents for allergic rhinitis (hay fever) do not have the concept of utilizing the above physiological reactions. In order to utilize this physiological response, the accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa is eliminated by repeatedly inserting the agent of the present invention into the nasal cavity.
During the course of treatment with this drug, IgE antibodies are separated from the mast cells of the nasal mucosa, the accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa is eliminated, antigen-antibody reactions cease to occur, and allergic rhinitis ( Hay fever) is completely cured.
(6) In the course of treatment with this drug, the nasal mucosa is soaked with this drug, which is an organic acid with a pH of 3. IgE antibodies that cause allergies are separated from the mast cells of the nasal mucosa, and the nasal mucosa epithelial layer. Antibodies are separated from mast cells, and accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa, which triggers the onset of hay fever, is resolved, and antigen-antibody reactions cease to occur, and allergic rhinitis (hay fever) is completely cured.
（１）本願発明の剤は鼻粘膜の肥満細胞に附着しているＩｇＥ抗体を分離する生理反応により、アレルギー性鼻炎（花粉症）を完治させるための剤であり、以下の構成である。重量２０％の食用塩、重量９０％のクエン酸を主成分とする重量５％でＰＨ３の有機酸からなる剤を鼻腔の大きさに適した日本薬局方カプセル（例えば、＃００、＃０、＃等）に入れて使用する。
（２）鼻粘膜上皮層への感作肥満細胞の集積と、Ｔｈ２細胞が局所（鼻粘膜上皮）に誘導されて、Ｔｈ２優位な環境が成立して、初めて局所（鼻粘膜上皮層）でアレルギー性鼻炎（花粉症）が発症する。
（３）鼻粘膜の肥満細胞に附着しているＩｇＥ抗体を分離することにより、アレルギー性鼻炎（花粉症）を完治させるための剤である。本剤を鼻腔内に挿入し，鼻閉すると鼻粘膜層における塩と有機酸の酸による脱水・萎縮反応と、塩と有機酸による刺激とストレスを鼻粘膜に与えることにより、鼻粘膜の肥満細胞に付着しているＩｇＥ抗体が分離して鼻粘膜上皮層の感作肥満細胞の集積が解消して、抗原抗体反応が発生しなくなる。
（４）肥満細胞をＰＨ３の有機酸で処理すれば、肥満細胞表面のＦｃレセプターから血清由来のＩｇが分離する。
［非特許文献４］未来免疫学 安保徹著 インターメディカル社刊第二章気圧と酸素と白血球（Ｐ－４５～４６）１９９７年刊
これと同じ生理反応を発生させるために、上記の本剤で、３度９回治療する課程で、鼻粘膜上皮層に集積して、アレルギー性鼻炎（花粉症）の症状、および、炎症反応のトリガーになる肥満細胞の細胞膜表面のＦＣレセプターに附着しているＩｇＥ抗体が分離して、鼻粘膜上皮層の感作肥満細胞の集積が解消して、抗原抗体反応が発生しなくなる。その結果、アレルギー性鼻炎（花粉症）は完治する。
これら上記の解決策は、本剤を次に記す方法で使用することである。
（５）アレルギー性鼻炎（花粉症）の症状が発生した時に、本剤を鼻腔内に挿入し、発生する鼻汁が外部に流出しない処置をする。すると、鼻汁が発生し始め、鼻腔内に、鼻汁が溜まり始める。この反応を出来るだけ長く辛抱し、辛抱しきれなくなったら鼻をかみ続ける。数回から１０回程度、とにかく、鼻汁が出なくなるまで、鼻をかみ続ける。そして、鼻汁が出なくなれば。再度、本剤を鼻腔内に挿入すると、それが溶けて、その成分が、鼻粘膜層と、再度反応をおこし始める。すると、上記の様に鼻腔内に鼻汁が溜り始める。その反応を出来るだけ長く辛抱し 辛抱しきれなくなるか、これ以上鼻汁の発生量が増えないと判断すれば、初回と同様、鼻をかみ続ける。そして、再々度、本剤を鼻腔内に挿入し、鼻汁のたまるのを待ち、鼻汁が出なくなるまで、鼻をかみ続ける。鼻汁は、初回より２回目、２回目より３回目の方が、発生量が少なくなる。この３回の治療によって、アレルギー性鼻炎（花粉症）の症状である鼻汁の流出と鼻閉等の症状は、一時、解消する。
しかし、後日、また、アレルギー性鼻炎（花粉症）が発症する。その症状が、これ以上悪くならないと思った時に、２度目の治療をする。初回と同じ治療方法と治療回数を実施すれば、アレルギー性鼻炎（花粉症）が、解消する。そして、完全を期するために、後々日、発生するアレルギー性鼻炎（花粉症）の症状を見逃さず、３度目の治療を上記の様に実施する。
（６）上記を以下にさらに詳しく説明する。
△１▽Ａ，本剤を治療第１日目に鼻腔内に３回挿入、鼻閉して、３回のアレルギー性鼻炎（花粉症）の症状を進化させることによって鼻粘膜層からより多く鼻汁発生、流出させることによって、アレルギー性鼻炎（花粉症）の症状は、解消する。
Ｂ．後日、アレルギー性鼻炎（花粉症）の症状が、再発すれば、初回と同じ様に、２度目の治療をすることにより、アレルギー性鼻炎（花粉症）の症状は、解消する。
Ｃ．後々日、アレルギー性鼻炎（花粉症）の症状は、再々発する。初回と同じ様に、３度目の治療をすることにより、アレルギー性鼻炎（花粉症）は、解消し、次年度花粉症の季節になっても、再発しない。
△２△Ａ．鼻腔内粘膜で、アレルギー性鼻炎が発症すると、肥満細胞、好塩基球、好酸球、Ｂ細胞、Ｔｈ２細胞等々の浸潤細胞の数が、増加し、ヒミスタミン、ロイコトリエン等の放出により、鼻汁の流出・鼻閉・くしゃみ等の症状が発生する。この症状を、一時、進化させるために、本剤を鼻腔内に挿入して鼻閉する。すると、本剤に含まれた塩と有機酸による脱水・萎縮反応とＰＨ３の有機酸の酸と食用塩による刺激・ストレスにより、ヒスタミン・好酸球等を含んだ鼻汁がより多く発生・流出する。その結果、鼻粘膜上皮層等に存在するアレルギー性鼻炎（花粉症）の発症に係わる感作、高親和性受容体を細胞膜表面に多くもつ、あるいは、脱顆粒した 肥満細胞等々、および上皮直下の固有層から遊走して来る好酸球等々が、壊死するか、鼻腔外に流出して、その機能を喪失し、鼻粘膜上皮層は、刷新される。その結果、鼻粘膜上皮層の感作肥満細胞の集積が、解消する。
Ｂ．肥満細胞をＰＨ３の有機酸で処理すれば、肥満細胞表面のＦｃレセプターから血清由来のＩｇが分離する。これと同じ生理反応を発生させるために、上記の本剤で、３度９回治療する課程で、鼻粘膜上皮層に集積して、アレルギー性鼻炎（花粉症）の症状、および、炎症反応のトリガーになる肥満細胞の細胞膜表面のＦｃレセプターに附着しているＩｇＥ抗体が分離して、鼻粘膜上皮層の感作肥満細胞の集積が解消して、抗原抗体反応が発生しなくなり、アレルギー性鼻炎（花粉症）は完治する。
（７）上記△２▽のＡにより、アレルギー性鼻炎（花粉症）の発症に係わる鼻粘膜上皮層の肥満細胞等と、それらに附着する抗体，および，その他の浸潤細胞等が、その機能を喪失し、鼻粘膜上皮層が刷新される。同△２▽のＢにより、感作肥満細胞から、抗体が分離する。その結果、アレルギー性鼻炎（花粉症）は、完治する。(1) The agent of the present invention is an agent for completely curing allergic rhinitis (hay fever) by a physiological reaction that isolates IgE antibodies attached to mast cells in the nasal mucosa, and has the following composition. A Japanese Pharmacopoeia capsule (e.g., #00, #0, # etc.).
( 2 ) Accumulation of sensitized mast cells in the nasal mucosal epithelium and Th2 cells are induced locally (nasal mucosal epithelium) to establish a Th2 - dominant environment, and then locally (nasal mucosal epithelium) develops allergic rhinitis (hay fever) .
(3) It is an agent for completely curing allergic rhinitis (hay fever) by isolating the IgE antibody attached to the mast cells of the nasal mucosa. When this drug is inserted into the nasal cavity and the nose is blocked, dehydration and atrophy reactions are caused by salts and organic acids in the nasal mucosa layer, and stimulation and stress by the salts and organic acids are applied to the nasal mucosa, resulting in mast cells of the nasal mucosa. The IgE antibody adhering to the nasal mucosa is separated, the accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa is eliminated, and the antigen-antibody reaction no longer occurs.
(4) When mast cells are treated with organic acid of pH3, serum-derived Ig is separated from Fc receptors on the surface of mast cells.
[Non-Patent Document 4] Mirai Immunology, Toru Abo, Intermedical Co., Ltd., Chapter 2 Atmospheric Pressure, Oxygen and Leukocytes (P-45-46), 1997 During the course of 3 to 9 treatments, IgE accumulated in the nasal mucosa epithelial layer and attached to the FC receptor on the cell membrane surface of mast cells, which triggered the symptoms of allergic rhinitis (hay fever) and inflammatory reactions. Antibodies are separated, the accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa is eliminated, and antigen-antibody reactions no longer occur. As a result, allergic rhinitis (hay fever) is completely cured.
A solution to these above is to use the drug in the following manner.
(5) When symptoms of allergic rhinitis (hay fever) occur, insert this drug into the nasal cavity and take measures to prevent the resulting nasal discharge from flowing out. Then, nasal discharge begins to occur, and nasal discharge begins to accumulate in the nasal cavity. Patience with this reaction for as long as you can, and if you can't stand it, keep blowing your nose. Continue blowing your nose several to ten times, anyway, until the nasal discharge stops. And if the runny nose does not come out. When the drug is reinserted into the nasal cavity, it dissolves and its ingredients begin to react with the nasal mucosa layer again. Then, nasal discharge begins to accumulate in the nasal cavity as described above. If you endure the reaction for as long as you can, or if you decide that the amount of nasal discharge will not increase any more, continue blowing your nose as you did the first time. Then, insert this drug into the nasal cavity again and again, wait for nasal mucus to accumulate, and continue blowing your nose until nasal mucus disappears. The amount of nasal discharge produced is smaller in the second time than in the first time and less in the third time than in the second time. With these three treatments, the symptoms of allergic rhinitis (hay fever) , such as runoff of nasal discharge and nasal congestion, are temporarily relieved.
However, at a later date, allergic rhinitis (hay fever) also develops. When you think the symptoms won't get any worse, do the second treatment. Allergic rhinitis (hay fever) will disappear if the same treatment method and number of treatments as the first treatment are performed. Then, in order to ensure completeness, the third treatment is performed as described above without overlooking the symptoms of allergic rhinitis (hay fever) that will occur in the days to come.
(6) The above will be explained in more detail below.
△１▽A, By inserting this drug into the nasal cavity three times on the first day of treatment, nasal congestion, and developing symptoms of allergic rhinitis (hay fever ) three times, more nasal discharge from the nasal mucosa layer The symptoms of allergic rhinitis (hay fever ) are resolved by generating and draining.
B. If the symptoms of allergic rhinitis (hay fever) recur at a later date, the symptoms of allergic rhinitis (hay fever) will be resolved by performing the second treatment in the same manner as the first time.
C. A few days later, the symptoms of allergic rhinitis (hay fever) reappear. The allergic rhinitis (hay fever) was resolved by the third treatment, just like the first time, and did not recur even in the next hay fever season.
△2△A. When allergic rhinitis develops in the intranasal mucosa, the number of infiltrating cells such as mast cells, basophils, eosinophils, B cells, and Th2 cells increases, and the release of hismistamine , leukotrienes, etc. causes nasal discharge. Symptoms such as runoff, nasal congestion, and sneezing occur. In order to temporarily develop this symptom, this drug is inserted into the nasal cavity to block the nose. Then, due to the dehydration/atrophy reaction caused by the salt and organic acid contained in this drug, and the stimulation/stress caused by the acid of the pH3 organic acid and edible salt, more nasal discharge containing histamine, eosinophils, etc. is generated and discharged. . As a result, sensitization related to the onset of allergic rhinitis (hay fever) existing in the epithelial layer of the nasal mucosa, etc., with many high-affinity receptors on the cell membrane surface, degranulated mast cells, etc., and subepithelial mast cells Eosinophils migrating from the lamina propria become necrotic or flow out of the nasal cavity and lose their function, and the nasal mucosal epithelial layer is renewed. As a result, the accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa is resolved.
B. Treatment of mast cells with PH3 organic acids segregates serum-derived Ig from Fc receptors on the surface of mast cells. In order to generate the same physiological reaction as this, during the course of treatment with this drug 3 times and 9 times, it accumulates in the nasal mucosa epithelial layer, causing symptoms of allergic rhinitis (hay fever) and inflammatory reaction. The IgE antibody attached to the Fc receptor on the surface of the cell membrane of mast cells, which is the trigger, is separated, and the accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa is resolved, and antigen-antibody reactions no longer occur, causing allergic rhinitis. (hay fever) is completely cured.
(7) Due to A of △2▽ above, mast cells, etc. in the epithelial layer of the nasal mucosa involved in the onset of allergic rhinitis (hay fever) , antibodies attached to them, and other infiltrating cells, etc., will not function. lost, and the nasal mucosal epithelial layer is renewed. Antibodies are separated from the sensitized mast cells by B of △2▽. As a result, allergic rhinitis (hay fever) is completely cured.
医薬に関する審査基準 第３章 医薬発明の１．２．１「実施可能要件」によれば、上記本願発明の剤とその使用方法は、出願時の技術常識から当業者が化合物等を製造又は取得することができ、かつ、その化合物等を医薬用途に使用することができる場合に相当すると推認されるので、必ずしも、実施例、薬理試験結果の記載は、必要ないと思考できるが、下記に臨床試験によ実施例、薬理試験結果の薬理効果を記載する。
鼻粘膜の肥満細胞に付着しているＩｇＥ抗体を分離させ、アレルギー性鼻炎（花粉症）を完治させるための本願発明の剤は、以下の構成である。重量２０％の食用塩、重量９０％のクエン酸を主成分とする重量５％でＰＨ３の有機酸からなる 剤を鼻腔の大きさに適した日本薬局方カプセル（例えば．＃００、＃０、＃等）に入れて、前記の「課題を解決するための手段」、および、「発明を実施するための形態」に記載の様に使用した。
（１）年令 ５５才 男
アレルギー性鼻炎（花粉症）が、発生したので本剤を、鼻腔内に挿入し、発生する鼻汁が、外部に流出しない処置をした。しばらくすると本剤が溶けて、その成分が鼻粘膜層と生理反応を起し始めた。すると多くの鼻汁が発生し始め鼻腔内に鼻汁が溜まり始めた。この反応を出来るだけ長く辛抱して辛抱しきれなくなり、鼻をかみ続けた。数回から１０回以上、とにかく鼻汁が出なくなるまで、鼻をかみ続けた。そして、鼻汁が出なくなり、再度、本剤を鼻腔内に挿入すると、それが溶けて、その成分が鼻粘膜層と生理反応をおこし始めた。すると、上記の様に鼻腔内に鼻汁が溜り始めた。その反応を出来るだけ長く辛抱し、辛抱しきれなくなり、これ以上、鼻汁の発生量が増えないと判断し、初回と同じ様に鼻をかみ続けた。そして、鼻汁が出なくなれば、初回と同じ様に再々度、本剤を鼻腔内に挿入し、鼻汁のたまるのを待ち、鼻汁が増えなくなったことが確認出来たので鼻汁が出なくなるまで鼻をかんだ。すると、鼻閉が解消し、第１日目の治療が、終った。
下記に、初回の治療から、治療が終了するまでの課程を整理する。
第１日目 １回目数回から１０回以上、鼻をかむと鼻汁が出なくなった。
（一度目） ２回目数回、鼻をかむと、鼻汁が出なくなった。
３回目２～３回、鼻をかむと、鼻汁が出なくなり。鼻閉が解消した。
後日、アレルギー性鼻炎（花粉症）の再発後、上記の様に２度目の治療をした。
第２日目 １回目数回、鼻をかむと、鼻汁が出なくなった。
（二度目） ２回目４回、鼻をかむと、鼻汁が出なくなった。
３回目２回、鼻をかむと、鼻汁が出なくなり、鼻閉が解消した。
後々日、アレルギー性鼻炎（花粉症）の再々発後、上記の様に、３度目の治療をした。
第３日目 １回目３回、鼻をかむと、鼻汁が出なくなった。
（三度目） ２回目２回、鼻をかむと、鼻汁が出なくなった。
３回目１回、鼻をかむと、鼻汁が出なくなり、鼻閉は解消した。
アレルギー性鼻炎（花粉症）の症状は、以後、次年度の花粉症の季節になっても再発せず、アレルギー性鼻炎（花粉症）が、完治したことが確認できた。
その結果、鼻粘膜の肥満細胞に附着しているＩｇＥ抗体を分離させる生理反応を発生させる本剤で３度９回の治療により、鼻粘膜の肥満細胞から、ＩｇＥ抗体が分離し、鼻粘膜上皮層の感作肥満細胞の集積が解消して、アレルギー性鼻炎（花粉症）が完治したことが、検証できた。
本願請求項に係わる発明は、従来技術の単なる花粉症の治療剤の様に、花粉症の症状を抑制する作用のある剤（特許文献１、２、非特許文献５、６参照）のように、アレルギー性鼻炎（花粉症）の症状を抑制する作用のある剤ではなく、本剤は、アレルギー性鼻炎（花粉症）の症状を体の正常な生理作用ととらえて本剤の鼻腔内挿入を繰り返すことにより、鼻粘膜の肥満細胞からＩｇＥ抗体が分離して、アレルギー性鼻炎（花粉症）の発症のトリガーになる感作肥満細胞の鼻粘膜上皮層への集積が解消する生理反応を発生させることによって、アレルギー性鼻炎（花粉症）を完治させる。しかし、既存の医学の治療剤は、花粉の飛散している季節には、それがなくなるまで、常時、薬を服用し続けなければ、花粉症の症状を抑制できず、アレルギー性鼻炎（花粉症）が完治することはない。
本願発明の請求項の剤を使用して治療することによって、上記の様に鼻粘膜の肥満細胞から、ＩｇＥ抗体が分離し、鼻粘膜上皮層の感作肥満細胞の集積が解消して、アレルギー性鼻炎（花粉症）は完治する。According to Examination Guidelines for Pharmaceuticals, Chapter 3, 1.2.1 “Enabling Requirement” for medicinal inventions, the agent of the present invention and the method of using the same can be manufactured or obtained by a person skilled in the art based on the common general knowledge as of the filing. It is presumed that this corresponds to the case where the compound, etc. can be used for medical purposes, so it is not necessarily necessary to describe Examples and pharmacological test results. Examples and pharmacological effects of pharmacological test results are described by test.
The agent of the present invention for separating IgE antibodies attached to mast cells in the nasal mucosa and completely curing allergic rhinitis (hay fever) has the following composition. 20% by weight of edible salt, 90% by weight of citric acid, and 5% by weight of an organic acid with a pH of 3 as the main ingredients are placed in Japanese Pharmacopoeia capsules suitable for the size of the nasal cavity (e.g., #00, #0). , # etc.) and used as described in the above "Means for Solving the Problems" and "Mode for Carrying Out the Invention".
(1) Age 55 years old male
Allergic rhinitis (hay fever) occurred, so this drug was inserted into the nasal cavity to prevent the resulting nasal discharge from flowing out. After a while, the drug dissolved, and its ingredients began to cause physiological reactions with the nasal mucosa layer. Then, a lot of nasal mucus began to occur and nasal mucus began to accumulate in the nasal cavity. I endured this reaction as long as I could and kept blowing my nose. I kept blowing my nose several times to 10 times or more until the nasal discharge stopped. When the nasal discharge ceased and the drug was reinserted into the nasal cavity, it dissolved and the ingredients began to react physiologically with the nasal mucosal layer. Then, nasal discharge began to accumulate in the nasal cavity as described above. I endured the reaction as long as possible, and when I could not endure it, I judged that the amount of nasal discharge would not increase any more, and continued blowing my nose in the same way as the first time. Then, when the nasal discharge stopped, insert this drug into the nasal cavity again in the same way as the first time, and wait for the nasal discharge to accumulate. Bite. Then, the nasal congestion resolved, and the treatment on the first day was completed.
Below is a summary of the course from the first treatment to the end of the treatment.
Day 1 Blowing the nose several times to 10 or more times stopped the discharge of nasal discharge.
(First time) When I blew my nose several times for the second time, nasal discharge stopped coming out.
Blow your nose 2-3 times for the 3rd time, and the nasal discharge will stop. Relieved nasal congestion.
At a later date, after a recurrence of allergic rhinitis (hay fever), a second treatment was given as described above.
2nd day After blowing the nose several times for the first time, nasal discharge stopped.
(Second time) When I blew my nose four times for the second time, nasal discharge stopped.
When the patient blew his nose twice for the third time, nasal discharge ceased and nasal congestion was resolved.
A few days later, after the recurrence of allergic rhinitis (hay fever), the patient was treated for the third time as described above.
On the 3rd day, when I blew my nose 3 times for the first time, nasal discharge stopped.
(Third time) When I blew my nose twice for the second time, nasal discharge stopped coming out.
When the patient blew his nose once for the third time, no nasal discharge was produced, and the nasal congestion was resolved.
The symptoms of allergic rhinitis (hay fever) did not recur even in the next year's hay fever season, and it was confirmed that the allergic rhinitis (hay fever) was completely cured.
As a result, the IgE antibody was isolated from the mast cells of the nasal mucosa by treatment with this drug, which generates a physiological reaction that separates the IgE antibodies attached to the mast cells of the nasal mucosa. It was verified that the accumulation of sensitized mast cells in the cortical layer was resolved and the allergic rhinitis (hay fever) was completely cured.
The invention according to the claims of the present application is an agent that suppresses the symptoms of hay fever (see Patent Documents 1 and 2, Non-Patent Documents 5 and 6), like the mere hay fever therapeutic agent of the prior art. This drug is not a drug that suppresses the symptoms of allergic rhinitis (hay fever) , but is intended to treat the symptoms of allergic rhinitis (hay fever) as a normal physiological action of the body and insert this drug into the nasal cavity. By repeating this process, IgE antibodies are separated from mast cells in the nasal mucosa, and a physiological reaction is generated that eliminates the accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa, which triggers the onset of allergic rhinitis (hay fever). This completely cures allergic rhinitis (hay fever) . However, existing medical therapeutic agents cannot control the symptoms of hay fever during the season when pollen is scattered, unless the drug is taken continuously until the hay fever disappears . ) is never cured.
By treatment with the agents claimed in the claims of the present invention, IgE antibodies are isolated from mast cells of the nasal mucosa as described above, the accumulation of sensitized mast cells in the epithelial layer of the nasal mucosa is resolved, and allergic reactions occur. Rhinitis (hay fever) is completely cured.
Claims (1)
前記有機酸のうちの重量９０％がクエン酸であり、
前記剤は、ｐＨ３であり、
鼻腔の大きさに適したカプセルに入れた前記剤を、鼻腔内に挿入後鼻孔を閉じ、その後、鼻孔を開放し鼻汁の出なくなるまで鼻をかむことで鼻汁を体外へ排出させる
花粉症によるアレルギー性鼻炎の治療のための剤。 An agent for treating allergic rhinitis due to hay fever, comprising 20% by weight of edible salt and 5% by weight of organic acid as ingredients,
90% by weight of the organic acid is citric acid;
The agent has a pH of 3 ,
After inserting the drug in a capsule suitable for the size of the nasal cavity into the nasal cavity, close the nostrils, then open the nostrils and blow the nose until no nasal discharge is produced to discharge the nasal secretions out of the body.
An agent for treating allergic rhinitis caused by hay fever.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2016/080039 WO2017061629A1 (en) | 2014-10-07 | 2016-10-03 | Drug for completely curing pollinosis by fulminating pollinosis symptom |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014233992 | 2014-10-07 | ||
| JP2014233992 | 2014-10-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016074692A JP2016074692A (en) | 2016-05-12 |
| JP7150409B2 true JP7150409B2 (en) | 2022-10-11 |
Family
ID=55949635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015225153A Active JP7150409B2 (en) | 2014-10-07 | 2015-10-06 | An agent for completely curing allergic rhinitis (hay fever) by isolating IgE antibodies attached to mast cells in the nasal mucosa. |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP7150409B2 (en) |
| WO (1) | WO2017061629A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7150409B2 (en) * | 2014-10-07 | 2022-10-11 | 勝詮 中山 | An agent for completely curing allergic rhinitis (hay fever) by isolating IgE antibodies attached to mast cells in the nasal mucosa. |
| US20190351207A1 (en) | 2017-01-25 | 2019-11-21 | Cosmed Pharmaceutical Co., Ltd. | Microneedle patch applying device |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10324635A (en) * | 1997-05-22 | 1998-12-08 | Katsuaki Nakayama | Anti-rhinitic and anti-allergic agent for treatment of viral and various allergic rhinitis and dermatitis |
| CN1299770C (en) * | 2004-05-31 | 2007-02-14 | 刘近周 | Multifunctional liquid for clean therapy of nasal cavity and sinuses |
| JP7150409B2 (en) * | 2014-10-07 | 2022-10-11 | 勝詮 中山 | An agent for completely curing allergic rhinitis (hay fever) by isolating IgE antibodies attached to mast cells in the nasal mucosa. |
-
2015
- 2015-10-06 JP JP2015225153A patent/JP7150409B2/en active Active
-
2016
- 2016-10-03 WO PCT/JP2016/080039 patent/WO2017061629A1/en active Application Filing
Non-Patent Citations (1)
| Title |
|---|
| 日本栄養・食糧学会誌，１９９５年，Ｖｏｌ．４８，ｐ．２３２－２３５ |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016074692A (en) | 2016-05-12 |
| WO2017061629A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rizaev et al. | Current View of the Problem: A New Approach to Covid-19 Treatment. | |
| Phillips et al. | Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrine. | |
| Bufe et al. | Specific immunotherapy in children | |
| JP7150409B2 (en) | An agent for completely curing allergic rhinitis (hay fever) by isolating IgE antibodies attached to mast cells in the nasal mucosa. | |
| Durham | Allergen immunotherapy (desensitisation) for allergic diseases | |
| Benichou et al. | A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double‐blind, placebo‐controlled study | |
| WO2016195723A1 (en) | Methods of treatment for conditions mediated by substance p | |
| KR102056118B1 (en) | A pharmaceutical composition for alleviating, treating or preventing allergic rhinitis | |
| Farrer | Sinusitis and allergic rhinitis | |
| TWI631946B (en) | Use of composition in manufacture of medicament for prevention or treatment of immune allergic airway disease | |
| Pullanikkad et al. | An Overview on Allergen Immunotherapy for Allergic Asthma with Emphasis on Subcutaneous and Sublingual Immunotherapy | |
| Schofield et al. | Recommended management and recent advances in allergic rhinitis | |
| Obukhanych | Herd Immunity: Myth or Reality | |
| JP2022188721A (en) | Direct therapy method for viral infection | |
| CN105343167A (en) | Nasal drop for easing joint movement and opening orifices | |
| Durham et al. | 1076 Grass pollen immunotherapy (IT) inhibits seasonal increases in Eosinophils and interleukin-5 mRNA positive cells in the nasal mucosa | |
| Bulyk et al. | CAN MELATONIN BE CONSIDERED AS A POTENTIAL EFFECTIVE ANTIVIRAL REMEDY AMID THE CORONAVIRUS PANDEMIC? | |
| Dominici | Vaccinazioni | |
| KL | Evaluation of the Effect of Pre-Operative Intra Nasal Steroid Spray Versus Oral Steroid on Intraoperative Bleed in Functional Endoscopic Sinus Surgery for Nasal Polyposis | |
| Bhandare et al. | AYURVEDIC APPROACH AS AN ADJUVANT THERAPY IN THE MANAGEMENT OF GHRANA NASHA IN COVID-19 PATIENTS WSR ANOSMIA–A REVIEW | |
| Shuxrat o’g | CAUSES OF THE ORIGIN OF RHINITIS DISEASE, TREATMENT, PREVENTION | |
| Çetin et al. | Treatment of Allergic Rhinitis: ENT Perspective | |
| Davis | Stop the sneezing and improve the breathing Managing allergic rhinitis: allergies | |
| Strachan | Guild: Ahh choo!: Common symptoms of colds and allergies | |
| Barnes et al. | Allergic rhinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181002 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191112 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200311 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200901 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201128 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201128 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201128 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210218 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210224 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20210326 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20210401 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20211119 |
|
| C27C | Written answer of applicant after an oral proceeding |
Free format text: JAPANESE INTERMEDIATE CODE: C2721 Effective date: 20211130 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220502 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20220517 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220603 |
|
| C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20220712 |
|
| C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20220816 |
|
| C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20220824 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7150409 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |